Intel HEXL: Accelerating Homomorphic Encryption with Intel AVX512-IFMA52

Modern implementations of homomorphic encryption (HE) rely heavily on polynomial arithmetic over a finite field. This is particularly true of the CKKS, BFV, and BGV HE schemes. Two of the biggest performance bottlenecks in HE primitives and applications are polynomial modular multiplication and the forward and inverse number-theoretic transform (NTT). Here, we introduce Intel Homomorphic Encryption Acceleration Library (Intel HEXL), a C++ library which provides optimized implementations of polynomial arithmetic for Intel processors. Intel HEXL takes advantage of the recent Intel Advanced Vector Extensions 512 (Intel AVX512) instruction set to provide state-of-the-art implementations of the NTT and modular multiplication. On the forward and inverse NTT, Intel HEXL provides up to 7.2x and 6.7x speedup, respectively, over a native C++ implementation. Intel HEXL also provides up to 6.0x speedup on the element-wise vector-vector modular multiplication, and 1.7x speedup on the element-wise vector-scalar modular multiplication. Intel HEXL is available open-source at https://github.com/intel/hexl under the Apache 2.0 license and has been adopted by the Microsoft SEAL and PALISADE homomorphic encryption libraries

Impact of Heat Pump Load on Distribution Networks

© The Institution of Engineering and Technology 2014. Heat pumps can provide domestic heating at a cost that is competitive with oil heating in particular. If the electricity supply contains a significant amount of renewable generation, a move from fossil fuel heating to heat pumps can reduce greenhouse gas emissions. The inherent thermal storage of heat pump installations can also provide the electricity supplier with valuable flexibility. The increase in heat pump installations in the UK and Europe in the last few years poses a challenge for low-voltage networks, because of the use of induction motors to drive the pump compressors. The induction motor load tends to depress voltage, especially on starting. The study includes experimental results, dynamic load modelling, comparison of experimental results and simulation results for various levels of heat pump deployment. The simulations are based on a generic test network designed to capture the main characteristics of UK distribution system practice. The simulations employ DIgSlILENT Power Factory to facilitate dynamic simulations that focus on starting current, voltage variations, active power, reactive power and switching transients

Belgian rare diseases plan in clinical pathology : identification of key biochemical diagnostic tests and establishment of reference laboratories and financing conditions

BackgroundOne objective of the Belgian Rare Diseases plan is to improve patients' management using phenotypic tests and, more specifically, the access to those tests by identifying the biochemical analyses used for rare diseases, developing new financing conditions and establishing reference laboratories.MethodsA feasibility study was performed from May 2015 until August 2016 in order to select the financeable biochemical analyses, and, among them, those that should be performed by reference laboratories. This selection was based on an inventory of analyses used for rare diseases and a survey addressed to the Belgian laboratories of clinical pathology (investigating the annual analytical costs, volumes, turnaround times and the tests unavailable in Belgium and outsourced abroad). A proposal of financeable analyses, financing modalities, reference laboratories' scope and budget estimation was developed and submitted to the Belgian healthcare authorities. After its approval in December 2016, the implementation phase took place from January 2017 until December 2019.ResultsIn 2019, new reimbursement conditions have been published for 46 analyses and eighteen reference laboratories have been recognized. Collaborations have also been developed with 5 foreign laboratories in order to organize the outsourcing and financing of 9 analyses unavailable in Belgium.ConclusionsIn the context of clinical pathology and rare diseases, this initiative enabled to identify unreimbursed analyses and to meet the most crucial financial needs. It also contributed to improve patients' management by establishing Belgian reference laboratories and foreign referral laboratories for highly-specific analyses and a permanent surveillance, quality and financing framework for those tests

A pesquisa em enfermagem: notas de ordem histórica e metodológica

O artigo se propõe a algumas considerações sobre a pesquisa em enfermagem no que se refere ao referencial teórico e caminhos metodológicos. Com esse intuito, seus autores resgatam o momento em que a enfermagem passa por um redirecionamento do método clássico de investigação para novas propostas metodológicas, contemplando outros objetos de estudo, possibilitando, assim, novos horizontes epistemológicos para a geração do conhecimento. Discutem questões relacionadas à coerência interna da pesquisa qualitativa, à observância de seus pressupostos filosóficos, ressaltando a importância da produção de conhecimentos que respondam às indagações do assistir e do cuidar em enfermagem.The article aims at making some considerations on nursing research in relation to this theoretical framework and methodological pathways. For that purpose the authors recapture the moment when nursing goes through a redirecting of the classical investigation method to new epistemological horizons for knowledge generation. The authors also discuss issues related to the internal coherence of qualitative research and the observance of philosophical premises emphasising the importance of the production of knowledge in response to queries on the assisting and caring in nursing

Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency

Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an autosomal recessive condition due to a deficiency of α-aminoadipic semialdehyde dehydrogenase, which is a key enzyme in lysine oxidation. PDE-ALDH7A1 is a developmental and epileptic encephalopathy that was historically and empirically treated with pharmacologic doses of pyridoxine. Despite adequate seizure control, most patients with PDE-ALDH7A1 were reported to have developmental delay and intellectual disability. To improve outcome, a lysine-restricted diet and competitive inhibition of lysine transport through the use of pharmacologic doses of arginine have been recommended as an adjunct therapy. These lysine-reduction therapies have resulted in improved biochemical parameters and cognitive development in many but not all patients. The goal of these consensus guidelines is to re-evaluate and update the two previously published recommendations for diagnosis, treatment, and follow-up of patients with PDE-ALDH7A1. Members of the International PDE Consortium initiated evidence and consensus-based process to review previous recommendations, new research findings, and relevant clinical aspects of PDE-ALDH7A1. The guideline development group included pediatric neurologists, biochemical geneticists, clinical geneticists, laboratory scientists, and metabolic dieticians representing 29 institutions from 16 countries. Consensus guidelines for the diagnosis and management of patients with PDE-ALDH7A1 are provided. This article is protected by copyright. All rights reserved

Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to alpha-aminoadipic semialdehyde dehydrogenase deficiency

Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an autosomal recessive condition due to a deficiency of α-aminoadipic semialdehyde dehydrogenase, which is a key enzyme in lysine oxidation. PDE-ALDH7A1 is a developmental and epileptic encephalopathy that was historically and empirically treated with pharmacologic doses of pyridoxine. Despite adequate seizure control, most patients with PDE-ALDH7A1 were reported to have developmental delay and intellectual disability. To improve outcome, a lysine-restricted diet and competitive inhibition of lysine transport through the use of pharmacologic doses of arginine have been recommended as an adjunct therapy. These lysine-reduction therapies have resulted in improved biochemical parameters and cognitive development in many but not all patients. The goal of these consensus guidelines is to re-evaluate and update the two previously published recommendations for diagnosis, treatment, and follow-up of patients with PDE-ALDH7A1. Members of the International PDE Consortium initiated evidence and consensus-based process to review previous recommendations, new research findings, and relevant clinical aspects of PDE-ALDH7A1. The guideline development group included pediatric neurologists, biochemical geneticists, clinical geneticists, laboratory scientists, and metabolic dieticians representing 29 institutions from 16 countries. Consensus guidelines for the diagnosis and management of patients with PDE-ALDH7A1 are provided. This article is protected by copyright. All rights reserved